Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 12
Submit an article Journal homepage
34
Views
10
CrossRef citations to date
0
Altmetric
Miscellaneous

Patent focus on cancer chemotherapeutics V. Angiogenesis agents: September 2001 – August 2002

Richard D Connell Pfizer Global Research & Development, Pfizer Corporation, MS 8118W-B3, Eastern Point Road, Groton, CT 06340, USA
Pages 1763-1782 | Published online: 25 Feb 2005

Bibliography

  • RIBATTI D, VACCA A, NICO B, RONCALI L, DAMMACCO F: Postnatal vasculogenesis. Mech. Dev. (2001) 100(2):157–163.
  • BROCK CS, LEE SM: Antiangiogenic strategies and vascular targeting in the treatment of lung cancer. Ear: Resp. (2002) 19(3):557–570.
  • HERBST RS, HIDALGO M, PIERSON AS, HOLDEN SN, BERGEN M, ECKHARDT SG: Angiogenesis inhibitors in clinical development for lung cancer. Semin. Oncol. (2002) 29(1 Supp1.4):66–77.
  • GOEL S, MANI S, PEREZ-SOLER R: Tyrosine kinase inhibitors: a clinical perspective. Current Oncology Reports (2002) 4(1):9–19.
  • CONNELL RD: Cancer chemotherapeutics - angiogenesis agents: October 1999 - March 2000. Expert Opin. Ther. Patents (2000) 10(6):767–786.
  • CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics. II angiogenesis agents: April 2000 - September (2000). Expert Opin. Ther. Patents (2001) 11(1):77–114.
  • CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics. III Angiogenesis agents: October 2000 - March 2001. Expert Opin. Ther. Patents(2001) 11(7):1171–1203.
  • CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics. IV Angiogenesis agents: April 2001 - August 2001. Expert Opin. Ther. Patents (2001) 11(12):1919–1945.
  • YANA I, SEIKI M: MT-MMPs play pivotal roles in cancer dissemination. Clin. Exp. Metastasis (2002) 19(3):209–215.
  • VIHINEN P, KAHARI VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. Cancer (2002) 99(2):157–166.
  • JACKSON C: Matrix metalloproteinases and angiogenesis. Can: Opin. Nephrol. Hyperten. (2002) 11(3):295–299.
  • DOHERTY TM, ASOTRA K, PEI DQ et al: Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin. Ther. Patents (2002) 12(5):665–707.
  • ••An excellent, up-to-date review of thepatent field around IVIIVIPIs.
  • WESTLIN WF: Integrins as targets of angiogenesis inhibition. Cancer J. (2001) 7\(Suppl. 3):5139–43.
  • COOPER CR, CHAY CH, PIENTA KJ: The role of a(v)I3(3) in prostate cancer progression. Neoplasia (2002) 4(3):191–194.
  • AL-OBEIDI FA, LAM KS: Development of inhibitors for protein tyrosine kinases. Oncogene (2000) 19:5690–5701.
  • ••A review of the most relevant TKIs described in the literature over the past 5 years.
  • LEVITZKI A: Protein tyrosine kinase inhibitors as therapeutic agents. Bioorg. Chem. Biol. Signal Transduction (2001) 211:1–15.
  • DUMAS J: Protein kinase inhibitors: emerging pharmacophores 1997-2000. Expert Opin. Ther. Patents (2001) 11(3):405–429.
  • ZWICK E, BANGE J, ULLRICH A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Ma Med. (2002) 8(1):17–23.
  • HICKLIN DJ, WITTE L, ZHU ZP et al: Monoclonal antibody strategies to block angiogenesis. Drug Discovery Today (2001) 6(10):517–528.
  • WOOLF AS, YUAN HT: Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatric Nephrology (2001) 16(2):177–184.
  • JONES N, ILJIN K, DUMONT DJ, ALITALO K: Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nature Reviews Molecular Cell Biology (2001) 2(0257–267.
  • Abbott confident Synthroid will stay on US market Scrip, July 2, 2001.
  • SHEWCHUK LM, HASSELL AM, ELLIS B et al.: Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop and C-terminal tail. Structure (2000) 8(11):1105–1113.
  • JEFFERS M, SHIMKETS R, PRAYAGA S et al.: Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res. (2001) 61(7):3131–3138.
  • PANDEY A, VOLKOTS DL, SEROOGYJ et al.: Discovery of CT53518, a potent and oral inhibitor of FLT3 kinase targeted for the treatment of acute myelogenous leukaemia. 223rd ACS National Meeting, Orlando, USA (2002) MEDI 19.
  • HENNEQUIN LF, STOKES ESE, THOMAS AP et al.: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure-activity relationship of a series of potent, orally-active, VEGF receptor tyrosine kinase inhibitors. .Med. Chem. (2002) 45(6):1300–1312.
  • •A nice review on the design and optimisation leading to ZD-6474.
  • WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumour growth after oral administration. Cancer Res. (2000) 60(8):2178–89.
  • BOLD G, FREI J, FURET P et al: CGP 79787D (PTK787/ZK222584), CGP 84738 NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bEGF-induced angiogenesis. Drugs of the Future (2002) 27(1):43–55.
  • DREVS J, MULLER-DRIVER R, WITTIG C et al: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumour vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. (2002) 62 (14):4015–4022.
  • ARRINGTON KL, COLL KE, FRALEY ME et al.: Development of 3-aryl-5-(3-indoly0pyridines as a novel class of KDR kinase inhibitors. 223rd ACS National Meeting, Orlando, USA (2002) MEDI 187.
  • HOFFMAN WE ARRINGTON KL, COLL KE et al: Design and synthesis of 2-acylamino-5-arylsubstituted oxazoles as kinase inhibitors of the VEGF receptor KDR. 223rd ACS National Meeting, Orlando, USA (2002) MEDI 181.
  • BILODEAU MT, COLL KE, CUNNINGHAM AM et al: Development and in vivo evaluation of novel inhibitors of the VEGF receptor tyrosine kinase KDR (VEGFR-2). 223rd ACS National Meeting Orlando, USA (2002) MEDI 261.
  • FRALEY ME, ARRINGTON KL, COLL KE et al.: Design, synthesis and in vitro/in vivo characterization of three novel classes of VEGFR-2 (KDR) kinase inhibitors. 93rd Annual meeting of the American Association of Cancer Research (AACR) San Francisco, CA, USA (2002) Abstract 3676.
  • TOLCHER A, KARP DD, O'LEARY JJ et al.: A Phase I and biologic correlative study of an oral Vascular Endothelial Growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (PTS) with advanced solid tumours. 38th annual meeting of theAmer. Soc. Clin. Omni, Orlando FL, USA (2002) Abstract 334

Websites

  • http://www.regeneron.com/company-press.asp Regeneron initiates clinical trial of VEGF trap in cancer November 28, 2001.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.